Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + pembrolizumab + bevacizumab
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab tirumotecan + pembrolizumab + bevacizumab is an investigational combination regimen being evaluated for the treatment of advanced cancers, specifically as a first-line maintenance therapy for persistent, recurrent, or newly diagnosed metastatic cervical cancer with PD-L1 combined positive score (CPS) ≥1. The regimen combines sacituzumab tirumotecan (sac-TMT; MK-2870; SKB264), a trophoblast glycoprotein (TROP2)-directed antibody-drug conjugate (ADC) carrying a topoisomerase I inhibitor payload; pembrolizumab (Keytruda), a programmed cell death protein 1 (PD-1)-blocking monoclonal antibody; and bevacizumab (Avastin), a vascular endothelial growth factor (VEGF)-targeting monoclonal antibody. This combination is designed to simultaneously target tumor cells via TROP2, enhance anti-tumor immune responses by blocking the PD-1/PD-L1 pathway, and inhibit angiogenesis by targeting VEGF. It is currently being evaluated in the Phase 3 TroFuse-036/GOG-3123/ENGOT-cx22 clinical trial.
- Other names
- MK-2870 + MK-3475 + bevacizumabMK-2870 + pembrolizumab + bevacizumabsac-TMT + pembrolizumab + bevacizumabsacituzumab tirumotecan + pembrolizumab + bevacizumab regimenSKB264 + pembrolizumab + bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on sacituzumab tirumotecan + pembrolizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + pembrolizumab + bevacizumab.